Aliases & Classifications for Paraplegia

Aliases & Descriptions for Paraplegia:

Name: Paraplegia 12 50 42 14 69
Severe or Complete Loss of Motor Function in the Lower Extremities and Lower Portions of the Trunk 50
Paraplegia, Lower 12

Classifications:



External Ids:

Disease Ontology 12 DOID:607
ICD10 33 G82.2 G82.20
ICD9CM 35 344.1
MeSH 42 D010264
NCIt 47 C50687
SNOMED-CT 64 155031004 60389000
UMLS 69 C0030486

Summaries for Paraplegia

MalaCards based summary : Paraplegia, also known as severe or complete loss of motor function in the lower extremities and lower portions of the trunk, is related to spastic paraplegia 51, autosomal recessive and spastic paraplegia 9a, autosomal dominant, and has symptoms including hemiplegia, ophthalmoplegia and paraparesis. An important gene associated with Paraplegia is SPG7 (SPG7, Paraplegin Matrix AAA Peptidase Subunit), and among its related pathways/superpathways is Endocytosis. The drugs Acetazolamide and diuretics have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and bone, and related phenotypes are behavior/neurological and nervous system

Wikipedia : 71 Paraplegia is an impairment in motor or sensory function of the lower half (legs) . The word comes from... more...

Related Diseases for Paraplegia

Diseases related to Paraplegia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 468)
id Related Disease Score Top Affiliating Genes
1 spastic paraplegia 51, autosomal recessive 33.1 SPG11 SPG21 SPG7
2 spastic paraplegia 9a, autosomal dominant 33.1 REEP1 RTN2 SPAST SPG20 ZFYVE27
3 spastic paraplegia facial cutaneous lesions 32.7 ATL1 KIF1A
4 hereditary spastic paraplegia 72 32.6 ATL1 NIPA1 REEP1 RTN2 SPAST SPG11
5 laurence-moon syndrome 31.3 PNPLA6 REEP1 RTN2 ZFYVE26
6 leukodystrophy, hypomyelinating, 4 31.1 ATL1 HSPD1 REEP1 SPAST
7 spastic ataxia 3, autosomal recessive 29.7 HSPD1 PLP1
8 hydrocephalus 28.9 ATL1 CYP7B1 HSPD1 KIF1A KIF5A NIPA1
9 sitosterolemia 28.6 ATL1 NIPA1 REEP1 RTN2 SLC33A1 SPAST
10 hereditary spastic paraplegia 12.3
11 spastic paraplegia 7, autosomal recessive 12.2
12 spastic paraplegia 2, x-linked 12.2
13 silver spastic paraplegia syndrome 12.2
14 spastic paraplegia 11 12.1
15 spastic paraplegia 4 12.1
16 spastic paraplegia 11, autosomal recessive 12.1
17 spastic paraplegia 49, autosomal recessive 12.1
18 spastic paraplegia 39, autosomal recessive 12.1
19 spastic paraplegia 72, autosomal recessive 12.1
20 spastic paraplegia 5a, autosomal recessive 12.1
21 spastic paraplegia 15, autosomal recessive 12.1
22 spastic paraplegia 4, autosomal dominant 12.1
23 spastic paraplegia 6, autosomal dominant 12.1
24 spastic paraplegia 8 12.1
25 spastic paraplegia 54, autosomal recessive 12.1
26 spastic paraplegia, optic atrophy, and neuropathy 12.1
27 spastic paraplegia 3a, autosomal dominant 12.1
28 spastic paraplegia 10, autosomal dominant 12.1
29 spastic paraplegia 3a 12.1
30 spastic paraplegia 30, autosomal recessive 12.1
31 spastic paraplegia 56, autosomal recessive 12.1
32 spastic paraplegia 46, autosomal recessive 12.1
33 spastic paraplegia 28, autosomal recessive 12.1
34 spastic paraplegia 35, autosomal recessive 12.1
35 spastic paraplegia 43, autosomal recessive 12.1
36 spastic paraplegia 45, autosomal recessive 12.1
37 spastic paraplegia 18, autosomal recessive 12.1
38 spastic paraplegia 8, autosomal dominant 12.1
39 spastic paraplegia 26, autosomal recessive 12.1
40 spastic paraplegia 61, autosomal recessive 12.1
41 spastic paraplegia 12, autosomal dominant 12.1
42 spastic paraplegia 57, autosomal recessive 12.1
43 spastic paraplegia 63 12.1
44 spastic paraplegia 31, autosomal dominant 12.1
45 spastic paraplegia 42, autosomal dominant 12.1
46 spastic paraplegia 48, autosomal recessive 12.1
47 spastic paraplegia 55, autosomal recessive 12.1
48 hereditary spastic paraplegia 3a 12.1
49 troyer syndrome 12.0
50 spastic paraplegia 44, autosomal recessive 12.0

Comorbidity relations with Paraplegia via Phenotypic Disease Network (PDN): (show all 13)


Acute Cystitis Decubitus Ulcer
Deficiency Anemia Heart Disease
Hypertension, Essential Multiple Sclerosis, Disease Progression, Modifier of
Neurogenic Bladder Osteoporosis
Paralytic Ileus Prostate Cancer
Protein-Energy Malnutrition Spinal Cord Disease
Vascular Myelopathy

Graphical network of the top 20 diseases related to Paraplegia:



Diseases related to Paraplegia

Symptoms & Phenotypes for Paraplegia

UMLS symptoms related to Paraplegia:


hemiplegia, ophthalmoplegia, paraparesis, paraplegia, ataxic, monoparesis, paraplegia, cerebral, paraplegia, spinal, monoplegia of lower limb affecting unspecified side, paraplegia, flaccid

MGI Mouse Phenotypes related to Paraplegia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.8 REEP1 SLC33A1 SPAST SPG11 SPG7 ZFYVE26
2 nervous system MP:0003631 9.4 DDHD2 HSPD1 KIF1A KIF5A PLP1 PNPLA6

Drugs & Therapeutics for Paraplegia

Drugs for Paraplegia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 100)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
2 diuretics Phase 4
3 Natriuretic Agents Phase 4
4 Anticonvulsants Phase 4
5 Carbonic Anhydrase Inhibitors Phase 4
6
Minocycline Approved, Investigational Phase 2, Phase 3 10118-90-8 5281021
7
Acetylcholine Approved Phase 2, Phase 3 51-84-3 187
8 Anti-Bacterial Agents Phase 2, Phase 3
9 Anti-Infective Agents Phase 2, Phase 3
10 Cholinergic Agents Phase 2, Phase 3
11 Neurotransmitter Agents Phase 2, Phase 3,Phase 1
12 Fibrin Tissue Adhesive Phase 2, Phase 3,Phase 1
13 Botulinum Toxins Phase 2, Phase 3
14 Cortivazol Phase 3
15 Anti-Inflammatory Agents Phase 3,Phase 2
16
Dopamine Approved Phase 1, Phase 2 51-61-6, 62-31-7 681
17
Levodopa Approved Phase 1, Phase 2 59-92-7 6047
18
Buspirone Approved, Investigational Phase 1, Phase 2 36505-84-7 2477
19
Carbidopa Approved Phase 1, Phase 2 28860-95-9 34359 38101
20
chenodeoxycholic acid Approved Phase 2 474-25-9 10133
21
Resveratrol Experimental, Investigational Phase 2 501-36-0, 955365-80-7 24856436 445154
22 Analgesics Phase 2
23
Serotonin Phase 1, Phase 2 50-67-9 5202
24 Serotonin Agents Phase 1, Phase 2
25 Neuromuscular Agents Phase 2
26 Hemagglutinins Phase 2
27 Tranquilizing Agents Phase 1, Phase 2
28 Peripheral Nervous System Agents Phase 2
29 Dopamine Agents Phase 1, Phase 2
30 Pharmaceutical Solutions Phase 2
31 Anti-Anxiety Agents Phase 1, Phase 2
32 abobotulinumtoxinA Phase 2
33 incobotulinumtoxinA Phase 2
34 onabotulinumtoxinA Phase 2
35 Psychotropic Drugs Phase 1, Phase 2
36 Botulinum Toxins, Type A Phase 2
37 Carbidopa, levodopa drug combination Phase 1, Phase 2
38 Antiparkinson Agents Phase 1, Phase 2
39 Central Nervous System Depressants Phase 1, Phase 2
40 Hypolipidemic Agents Phase 2
41 Lipid Regulating Agents Phase 2
42 Antimetabolites Phase 2
43 Atorvastatin Calcium Phase 2 134523-03-8
44 Gastrointestinal Agents Phase 2
45 Analgesics, Non-Narcotic Phase 2
46 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
47 Platelet Aggregation Inhibitors Phase 2
48 Anticholesteremic Agents Phase 2
49 Protective Agents Phase 2
50 Laxatives Phase 2

Interventional clinical trials:

(show top 50) (show all 95)
id Name Status NCT ID Phase
1 Effectiveness of Acetazolamide in Reducing Paralysis of the Leg in Patients Undergoing Aortic Aneurysm Surgery Surgery Unknown status NCT01889498 Phase 4
2 Brain Function and White Matter Changes in Congenital, Acute and Chronic Spinal Cord Lesions Completed NCT01208584 Phase 4
3 Effect of Heat Exposure on Cognition in Persons With Tetraplegia Recruiting NCT02488824 Phase 4
4 Prevention of Imminent Paralysis Following Spinal Cord Trauma or Ischemia by Minocycline: A Multi-center Study in Israel With IDF Primary Care Involvement Unknown status NCT01813240 Phase 2, Phase 3
5 Retraining Walking After Spinal Cord Injury Unknown status NCT00059553 Phase 2, Phase 3
6 Comparison of a Cortivazol (ALTIM®) Infiltration of Posterior Epidural Space at L3-L4 Stage Versus an Epidural Infiltration of Cortivazol (ALTIM®) on Contact With Disco Radicular Conflict in Discal Sciatica Recruiting NCT02151045 Phase 3
7 Effects of Botulinum Toxin Injections in Patients With Hereditary Spastic Paraplegia Active, not recruiting NCT02604186 Phase 2, Phase 3
8 Study of the Impact of the Use of a Corset on the Respiratory Function of Patients With Spinal Cord Injury Withdrawn NCT01569360 Phase 3
9 Cethrin in Acute Cervical Spinal Cord Injury Withdrawn NCT02053883 Phase 2, Phase 3
10 Spinal Cord Injury Leg Rehabilitation Completed NCT01498991 Phase 1, Phase 2
11 Treatment With Xeomin Versus Botox in Children With Spastic Equine and Equinovarus Foot Deformation in Pediatric Cerebral Palsy Completed NCT02188277 Phase 2
12 The Effects of Passive Gait Training in Complete Motor Spinal Cord Injury (SCI) Completed NCT01349478 Phase 1, Phase 2
13 A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries Completed NCT00500812 Phase 1, Phase 2
14 Study to Assess Safety, Tolerability and MTD of a Central Pattern Generator-activating Tritherapy (SPINALON) in Patients With Chronic Spinal Cord Injury Completed NCT01484184 Phase 1, Phase 2
15 Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5 Active, not recruiting NCT02314208 Phase 2
16 Neural Stem Cell Transplantation in Traumatic Spinal Cord Injury Active, not recruiting NCT02326662 Phase 1, Phase 2
17 Epidural Stimulation After Neurologic Damage Not yet recruiting NCT03026816 Phase 2
18 Autologous Mesenchymal Stem Cells Transplantation in Thoracolumbar Chronic and Complete Spinal Cord Injury Spinal Cord Injury Not yet recruiting NCT02574585 Phase 2
19 Autologous Incubated Macrophages for Patients With Complete Spinal Cord Injuries Suspended NCT00073853 Phase 2
20 Pressure Ulcer Formation Prevention in Paraplegics Using Computer and Sensory Substitution Via the Tongue. Terminated NCT00429013 Phase 2
21 The ReWalk Exoskeletal Walking System for Persons With Paraplegia Unknown status NCT01454570 Phase 1
22 SPATAX: Clinical and Genetic Analysis of Cerebellar Ataxias and Spastic Paraplegias Unknown status NCT00140829 Phase 1
23 Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations Unknown status NCT00136630 Phase 1
24 Orthostatic Tolerance During FES (Functional Electrical Stimulation)-Walking in Paraplegia Completed NCT00108043 Phase 1
25 Safety of Autologous Human Schwann Cells (ahSC) in Subjects With Subacute SCI Completed NCT01739023 Phase 1
26 Use of Interactive Gaming for Enhanced Function After Spinal Cord Injury Completed NCT01537978 Phase 1
27 Safety Study of Local Administration of Autologous Bone Marrow Stromal Cells in Chronic Paraplegia Completed NCT01909154 Phase 1
28 The Safety of ahSC in Chronic SCI With Rehabilitation Recruiting NCT02354625 Phase 1
29 Improving Ambulatory Community Access After Paralysis Active, not recruiting NCT01570816 Phase 1
30 Cohorts and Collections: Clinical and Genetic Study of Parkinson's Disease and Epilepsies Terminated NCT00142363 Phase 1
31 Evaluation of a Hybrid Prototype Strategy (Electrostimulation of Lower Limb Muscles Associated With Voluntary Strengthening of the Upper Limbs) in Reconditioning to Effort in Patients With Chronic Paraplegia. Unknown status NCT02042508
32 Reciprocating Gait Orthoses for Paraplegia Patients Unknown status NCT02227407
33 Adjusting Wheelchair Set-Up to Minimize Shoulder Joint Forces During Propulsion Unknown status NCT00785278
34 Abdominal Functional Electrical Stimulation in Tetraplegia Unknown status NCT00202631
35 Effect of Intense Multi-modal Training on Bone Health and Quality of Life in Persons With Spinal Cord Injury Unknown status NCT01386762 Early Phase 1
36 Body Composition Assessment in Spinal Cord Injury Unknown status NCT00957762
37 Paraplegic Cycling: Improving Health After Spinal Cord Injury Unknown status NCT00204100
38 Nuclear Magnetic Spectroscopy Imaging to Evaluate Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral Sclerosis Completed NCT00023075
39 Effects of Exercise in People With Paraplegia Completed NCT01203150
40 Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis Completed NCT00838838
41 A Study Testing Safety and Tolerance of the ReWalk Exoskeleton Suit Completed NCT00627107
42 Safety and Performance Evaluation of ReWalk Reciprocating Gait Orthosis (RGO) Completed NCT01251549
43 Exercise to Reduce Obesity in Spinal Cord Injury Completed NCT00270855
44 Robotically Assisted Treadmill Training in Spinal Cord Injury (SCI) Completed NCT00385918
45 Finding the Optimal Voluntary Exercise Parameters for Those Living With Quadriplegia Completed NCT03146728
46 Medico-economical Impact of the Brindley Neurosurgical Technique in France Completed NCT00221767
47 Study of an Implantable Functional Neuromuscular Stimulation System for Patients With Spinal Cord Injuries Completed NCT00004445
48 Evaluation of the GORE® EXCLUDER® Iliac Branch Endoprosthesis Completed NCT01883999
49 Intrathecal Morphine on Transcranial Electric Motor-Evoked Potentials Completed NCT00596609
50 Feasibility of Telephone Counseling to Increase Physical Fitness in SCI Completed NCT02225028

Search NIH Clinical Center for Paraplegia

Cochrane evidence based reviews: paraplegia

Genetic Tests for Paraplegia

Anatomical Context for Paraplegia

MalaCards organs/tissues related to Paraplegia:

39
Spinal Cord, Brain, Bone, Heart, Testes, Thyroid, Lung

Publications for Paraplegia

Articles related to Paraplegia:

(show top 50) (show all 1258)
id Title Authors Year
1
De novo REEP2 missense mutation in pure hereditary spastic paraplegia. ( 28491902 )
2017
2
A Case of Acute Paraplegia Due to Aortic Dissection in Marfan Syndrome. ( 28479826 )
2017
3
Incomplete paraplegia caused by extramedullary hematopoiesis in a patient with thalassemia intermedia. ( 28503326 )
2017
4
Loss-of-function mutations in the ATP13A2/PARK9 gene cause complicated hereditary spastic paraplegia (SPG78). ( 28137957 )
2017
5
NT5C2 novel splicing variant expands the phenotypic spectrum of Spastic Paraplegia (SPG45): case report of a new member of thin corpus callosum SPG-Subgroup. ( 28327087 )
2017
6
Defects in ER-endosome contacts impact lysosome function in hereditary spastic paraplegia. ( 28389476 )
2017
7
A new phenotype associated with homozygous GRN mutations: complicated spastic paraplegia. ( 28000352 )
2017
8
Hereditary spastic paraplegia type 8 - neuropathological findings. ( 28181327 )
2017
9
Hereditary spastic paraplegia: More than an upper motor neuron disease. ( 28449883 )
2017
10
Studies on truncating mutations of SPAST associated with Hereditary Spastic Paraplegia indicate greater accumulation and toxicity of the M1 isoform of spastin. ( 28495799 )
2017
11
Beneficial effects of rapamycin in a Drosophila model for hereditary spastic paraplegia. ( 27909242 )
2017
12
Progressive hereditary spastic paraplegia caused by a homozygous KY mutation. ( 28488683 )
2017
13
TFG associated hereditary spastic paraplegia: an addition to the phenotypic spectrum. ( 28124177 )
2017
14
Considering Spastic Paraplegia Type 7 and Adult-Onset Alexander Disease. ( 28459923 )
2017
15
Hereditary spastic paraplegia due to a novel mutation of the REEP1 gene: Case report and literature review. ( 28099355 )
2017
16
Clinical and genetic study of hereditary spastic paraplegia in Canada. ( 27957547 )
2017
17
Exome sequencing reveals two FA2H mutations in a family with a complicated form of Hereditary Spastic Paraplegia and psychiatric impairments. ( 28017243 )
2017
18
PLA2G6 mutations associated with a continuous clinical spectrum from neuroaxonal dystrophy to hereditary spastic paraplegia. ( 28295203 )
2017
19
Hereditary spastic paraplegia caused by compound heterozygous mutations outside the motor domain of the KIF1A gene. ( 28332297 )
2017
20
Sequential bilateral complete rupture of the rectus femoris muscle in a patient with hereditary spastic paraplegia. ( 28264543 )
2017
21
ATPase-deficient mitochondrial inner membrane protein ATAD3A disturbs mitochondrial dynamics in dominant hereditary spastic paraplegia. ( 28158749 )
2017
22
Pathophysiology, diagnostic work-up and management of balance impairments and falls in patients with hereditary spastic paraplegia. ( 28471471 )
2017
23
Clinical exome sequencing for cerebellar ataxia and spastic paraplegia uncovers novel gene-disease associations and unanticipated rare disorders. ( 28179632 )
2017
24
Considering Spastic Paraplegia Type 7 and Adult-Onset Alexander Disease-Reply. ( 28459933 )
2017
25
Posterior-only vertebral column resection for revision surgery in post-laminectomy rotokyphoscoliosis associated with late-onset paraplegia: A case report and literature review. ( 28072705 )
2017
26
ALS and MMN mimics in patients with BSCL2 mutations: the expanding clinical spectrum of SPG17 hereditary spastic paraplegia. ( 27738760 )
2017
27
Infusion of autologous adipose tissue derived neuronal differentiated mesenchymal stem cells and hematopoietic stem cells in post-traumatic paraplegia offers a viable therapeutic approach. ( 27110548 )
2016
28
A novel frameshift mutation of DDHD1 in a Japanese patient with autosomal recessive spastic paraplegia. ( 27216551 )
2016
29
Rapid Neurological Recovery Following Partial Surgical Resection of Spinal Glioblastoma Multiforme in a Pediatric Patient Presenting With Complete Paraplegia. ( 27403775 )
2016
30
Identification of a novel SPG4 tandem base substitution in a Chinese hereditary spastic paraplegia family. ( 27942873 )
2016
31
Towards Parameters and Protocols to Recommend FES-Cycling in Cases of Paraplegia: A Preliminary Report. ( 27990239 )
2016
32
Impact of Moderate-intensity Exercise on Metabolic Health and Aerobic Capacity in Persons with Chronic Paraplegia: 1569 Board #222 June 2, 8: 00 AM - 9: 30 AM. ( 27360488 )
2016
33
Whole-genome sequencing of two probands with hereditary spastic paraplegia reveals novel splice-donor region variant and known pathogenic variant in SPG11. ( 27900367 )
2016
34
Coexistence of Factor VII Deficiency and Hereditary Spastic Paraplegia in Two Siblings. ( 28018685 )
2016
35
Hereditary spastic paraplegia: Novel mutations and expansion of the phenotype variability in SPG56. ( 26936192 )
2016
36
Novel De Novo Mutations in KIF1A as a Cause of Hereditary Spastic Paraplegia With Progressive Central Nervous System Involvement. ( 27034427 )
2016
37
Homozygous mutation in Atlastin GTPase 1 causes recessive hereditary spastic paraplegia. ( 26888483 )
2016
38
Non-motor symptoms in patients with hereditary spastic paraplegia caused by SPG4 mutations. ( 26806216 )
2016
39
Clinical and Paraclinical Indicators of Motor System Impairment in Hereditary Spastic Paraplegia: A Pilot Study. ( 27077743 )
2016
40
Acute myeloid leukemia presenting with complete paraplegia and bilateral total blindness due to central nervous system involvement. ( 28053737 )
2016
41
SPAST mutation spectrum and familial occurrence among Czech patients with pure hereditary spastic paraplegia. ( 27334366 )
2016
42
Are low levels of 25(OH) vitamin D and testosterone clinically relevant in men with paraplegia? ( 27077579 )
2016
43
Mutations in CAPN1 Cause Autosomal-Recessive Hereditary Spastic Paraplegia. ( 27153400 )
2016
44
Adenosine deaminase 2 deficiency presenting as spastic paraplegia and systemic vasculitis. ( 26914925 )
2016
45
Reep1 null mice reveal a converging role for hereditary spastic paraplegia proteins in lipid droplet regulation. ( 27638887 )
2016
46
Mutations in CAPN1 Cause Autosomal-Recessive Hereditary Spastic Paraplegia. ( 27259058 )
2016
47
De-novo KCNA2 mutations cause hereditary spastic paraplegia. ( 28032718 )
2016
48
Late-onset spastic paraplegia type 10 (SPG10) family presenting with bulbar symptoms and fasciculations mimicking amyotrophic lateral sclerosis. ( 27084214 )
2016
49
Identification of a Heterozygous SPG11 Mutation by Clinical Exome Sequencing in a Patient With Hereditary Spastic Paraplegia: A Case Report. ( 28119845 )
2016
50
The importance of understanding gait features in hereditary spastic paraplegia: accomplishments and next steps. ( 26946256 )
2016

Variations for Paraplegia

Copy number variations for Paraplegia from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 170541 3 155544315 155572167 Copy number SLC33A1 Paraplegias

Expression for Paraplegia

Search GEO for disease gene expression data for Paraplegia.

Pathways for Paraplegia

Pathways related to Paraplegia according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.44 KIF5A SPG20 SPG21 WASHC5 ZFYVE27

GO Terms for Paraplegia

Cellular components related to Paraplegia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum GO:0005783 9.81 ATL1 CYP7B1 PNPLA6 REEP1 RTN2 SLC33A1
2 axon GO:0030424 9.62 ATL1 KIF1A SPG11 ZFYVE27
3 midbody GO:0030496 9.58 SPAST SPG20 ZFYVE26
4 endoplasmic reticulum membrane GO:0005789 9.56 ATL1 CYP7B1 PNPLA6 REEP1 RTN2 SLC33A1
5 axon cytoplasm GO:1904115 9.43 KIF1A SPAST SPG7
6 endoplasmic reticulum tubular network GO:0071782 8.8 ATL1 REEP1 ZFYVE27
7 membrane GO:0016020 10.24 ATL1 CYP7B1 DDHD2 HSPD1 KIF5A NIPA1

Biological processes related to Paraplegia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 lipid particle organization GO:0034389 8.96 DDHD2 SPG20
2 anterograde axonal transport GO:0008089 8.8 KIF1A SPAST SPG7

Molecular functions related to Paraplegia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 microtubule binding GO:0008017 8.92 KIF1A KIF5A REEP1 SPAST

Sources for Paraplegia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....